NEW YORK (GenomeWeb) – Sygnis today announced it has signed a non-exclusive agreement with GeneWorks for the distribution of its product portfolio in Australia.
Under the terms of the agreement, GeneWorks gains the rights to promote, market, and sell all existing and future Sygnis products, including TruePrime reagents for primer-free whole genome amplification and SunScript reverse transcriptase kits, in Australia.
"Over the recent months we experienced an increasing demand in our proprietary product and technology families, fueled by our extensive marketing activities and ongoing efforts to further expand our distribution network," Sygnis CEO and CFO Pilar de la Heurta said in a statement.
Financial and other terms of the deal were not disclosed.
Last week, Sygnis signed a non-exclusive deal with Nanodigmbio to distribute the firm's products in China. The firm also signed distribution deals earlier this year covering Taiwan, Canada, Japan, France, Belgium, the UK and Ireland, and Scandinavia.